ElevateBio - About the company
ElevateBio is a series D company based in Cambridge (United States), founded in 2018 by Mitchell Finer and David Hallal. It operates as a Provider of transnational research for portfolio of cell and gene therapy. ElevateBio has raised $1.25B in funding from investors like Matrix Capital Management, EDBI and Invus. The company has 536 active competitors, including 196 funded and 127 that have exited. Its top competitors include companies like Alnylam, Spark Therapeutics and Forge Biologics.
Company Details
Provider of transnational research for portfolio of cell and gene therapy. It offers transformative therapy along with other translational research like process development, cGMP manufacturing, clinical development, regulatory affairs, and commercial operations.
- Website
- elevate.bio
- Social
- Registered Address
- Cambridge, Massachusetts
Key Metrics
Founded Year
2018
Location
Cambridge, United States
Stage
Series D
Total Funding
$1.25B in 4 rounds
Latest Funding Round
Investors
Ranked
8th among 536 active competitors
Employee Count
452 as on Jul 31, 2026
Legal entities associated with ElevateBio
ElevateBio is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
ELEVATEBIO MANAGEMENT, INC. CIN: 823981863 , United States, Active | Dec 26, 999 | - | 468 (As on Dec 31, 2024) | - |
Sign up to download ElevateBio's company profile
ElevateBio's funding and investors
ElevateBio has raised a total funding of $1.25B over 4 rounds. Its first funding round was on May 13, 2019. Its latest funding round was a Series D round on May 24, 2023 for $*****. 15 investors participated in its latest round. ElevateBio has 18 institutional investors.
Here is the list of recent funding rounds of ElevateBio:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
May 24, 2023 | 7763688 | Series D | 9946411 | 4558056 | 5269084 | 2771515 |
Mar 15, 2021 | 4958522 | Series C | 5389248 | 7564561 | 9154044 | |
Mar 30, 2020 | 6922301 | Series B | 5534863 | 2062437 |
Access funding benchmarks and valuations. Sign up today!View details of ElevateBio's funding rounds and investors
ElevateBio's founders and board of directors
Founder? Claim ProfileThe founders of ElevateBio are Mitchell Finer and David Hallal.
Here are the details of ElevateBio's key team members:
- Mitchell Finer: Former Co-Founder of ElevateBio.
- David Hallal: Co-Founder of ElevateBio. Contact Info: 1 email address
View details of ElevateBio's Founder profiles and Board Members
ElevateBio's employee count trend
ElevateBio has 452 employees as of Jul 26. Here is ElevateBio's employee count trend over the years:
Uncover ElevateBio's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
ElevateBio's Competitors and alternates
Top competitors of ElevateBio include Alnylam, Spark Therapeutics and Forge Biologics. Here is the list of Top 10 competitors of ElevateBio, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Alnylam 2002, Cambridge (United States), Public | Developer of RNA interference-based therapeutics for multiple disorders | $17M | 79/100 | |
2nd | Spark Therapeutics 2013, Philadelphia (United States), Acquired | Developer of gene therapy for rare diseases | $82.8M | 73/100 | |
3rd |  Forge Biologics 2020, Columbus (United States), Acquired | Developer of gene therapeutic solutions for treating multiple diseases | $330M | 70/100 | |
4th |  Strand Therapeutics 2017, Cambridge (United States), Series B | Provider of platform to deliver mRNA therapeutics for multi functional treatments | $256M | 70/100 | |
5th | _1560516450043.png?devicePixelRatio=2&height=30&width=30){kind=logo} Passage Bio 2017, Philadelphia (United States), Public | Developer of gene therapies for CNS rare diseases | $226M | 69/100 | |
6th | Ultragenyx 2010, Novato (United States), Acquired | Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases | $135M | 69/100 | |
7th |  Generation Bio 2016, Cambridge (United States), Acquired | Developer of gene therapies for rare liver and eye diseases | $236M | 69/100 | |
8th | ElevateBio 2018, Cambridge (United States), Series D | Provider of transnational research for portfolio of cell and gene therapy | $1.25B | 69/100 | |
9th | Krystal Biotech 2015, Pittsburgh (United States), Public | Developer of genetic medicines to treat rare diseases | $11.3M | 67/100 | |
10th | Sirnaomics 2007, Gaithersburg (United States), Public | Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease | $267M | 67/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on ElevateBio's competitors? Click here to see the top ones
ElevateBio's Investments and acquisitions
ElevateBio has made 2 investments in Abata and AlloVir and acquired LifeEDIT.Here is the list of these investments and acquisitions:
Date of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Oct 27, 2021 | Acquisition | 2017 | Durham (United States) | |
Jun 04, 2021 | Investments | 2021 | Cambridge (United States) | |
May 21, 2019 | Investments | 2013 | Houston (United States) |
Want to know more about where corporates are investing? Sign up today!Reports related to ElevateBio
Here is the latest report on ElevateBio's sector:
News related to ElevateBio
Filter this listMedia has covered ElevateBio for a total of 4 events in the last 1 year, 2 of them have been about people movement and 1 about company updates.
•
Kyverna, ElevateBio Ink Manufacturing Agreement for Miv-Cel SupplyContract Pharma•Jul 27, 2026•ElevateBio, Kyverna Therapeutics
•
•
•
•
•
ElevateBio taps Amazon’s genAI tools to design CRISPR therapeuticsPharmaceutical Technology•Mar 11, 2025•ElevateBio, Amazon Web Services
•
ToneTag Secures US USD 78 Million in Funding to Transform Payment and CommerceBusinessnewsthisweek•Feb 25, 2025•ToneTag, ValueQuest, Iron Pillar, ElevateBio
•
Real Estate Notes: River North hotel project plan progresses ...Nashville Post•Feb 03, 2025•Nexera Energy, Emerge, ElevateBio, Kimley-Horn and 8 others
•
ElevateBio to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceBenzinga•Jan 09, 2025•ElevateBio
•
ElevateBio Appoints Amy Pooler, Ph.D., as Senior Vice President, Research and DevelopmentGlobeNewswire•Nov 04, 2024•ElevateBio
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about ElevateBio
Explore our recently published companies
- Salmonandsable - Unfunded company
- Order Asprigofthymesrq - Unfunded company
- Pizzatupwalthamabbey - United Kingdom based, Unfunded company
- Damascusbakeryandsweets - United Kingdom based, Unfunded company
- Alifishandchips - United Kingdom based, Unfunded company
- Pasam Pizza Kebab - Germany based, Unfunded company
